生物分析
人血浆
化学
药品
卟啉
色谱法
基质(化学分析)
等离子体
组合化学
药理学
生物化学
医学
量子力学
物理
作者
Hamza Kandoussi,Jianing Zeng,Kumar A. Shah,Patricia Paterson,Rasa Santockyte,Pathanjali Kadiyala,Hong Shen,Petia Shipkova,Robert A. Langish,Richard Burrrell,John A. Easter,Thomas Mariannino,Punit Marathe,Yurong Lai,Yan Zhang,Renuka Pillutla
出处
期刊:Bioanalysis
[Future Science Ltd]
日期:2018-05-01
卷期号:10 (9): 633-644
被引量:19
标识
DOI:10.4155/bio-2017-0246
摘要
Aim: Coproporphyrins (CP-I and CP-III) have been identified as possible biomarkers to predict human hepatic organic anion-transporting polypeptides-mediated-drug-interactions for a new drug entering clinical development. Results: The method is applicable to quantify plasma CP-I and CP-III within 0.078–15.0 nM. The results identify and address a number of challenges encountered with porphyrin assays such as photodegradation and interferences. To overcome interferences from ubiquitous porphyrins, a surrogate matrix was used to prepare calibration standards. Quality controls were prepared in plasma and surrogate matrix to ensure parallelism between surrogate matrix and plasma. Conclusion: A robust UHPLC–MS/MS assay was developed and validated for CP-I and CP-III in plasma, and is currently applied to clinical studies to confirm suitability of Coproporphyrins as a potential substitute for drug–drug interaction study.
科研通智能强力驱动
Strongly Powered by AbleSci AI